pharma Β· Duchenne Muscular Dystrophy Β· Muscular Dystrophies Β· CAPR
CAPRICOR THERAPEUTICS, INC.
CAPRICOR THERAPEUTICS drug portfolio β 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 6 drugs and development assets β regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CAPRICOR THERAPEUTICS drug portfolio β 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in CAPRICOR THERAPEUTICS's portfolio. Mechanism: Somatic cell supplemental therapy.
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
Development asset linked to CAPRICOR THERAPEUTICS in public FDA and regional records.
Development asset linked to CAPRICOR THERAPEUTICS in public FDA and regional records.
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
Development asset linked to CAPRICOR THERAPEUTICS in public FDA and regional records.